Pisake Lumbiganon

Pisake Lumbiganon

Auto-generated profile, based on publicly available information

Pisake Lumbiganon

Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2010 in BMC Medicine
Verified
Journal Article
Open access
PDF file
TGthe WHO Global Survey on Maternal and Perinatal Health Research Group
the WHO Global Survey on Maternal and Perinatal Health Research Group
JSJp Souza
Jp Souza
AGAm Gülmezoglu
Am Gülmezoglu
PLP Lumbiganon
P Lumbiganon
MLM Laopaiboon
M Laopaiboon
PRP Ruyan
P Ruyan
There is worldwide debate about the appropriateness of caesarean sections performed without medical indications. In this analysis, we aim to further investigate the relationship between caesarean section without medical indication and severe maternal outcomes.

18 March 2014 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
MLM Laopaiboon
M Laopaiboon
PLP Lumbiganon
P Lumbiganon
NIN Intarut
N Intarut
RMRintaro Mori
Rintaro Mori
TGT Ganchimeg
T Ganchimeg
ONon behalf of the WHO Multicountry Survey on Maternal Newborn Health Research Network
on behalf of the WHO Multicountry Survey on Maternal Newborn Health Research Network

12 April 2013 in Reproductive Health
Verified
Journal Article
Open access
PDF file
JVJoshua P Vogel
Joshua P Vogel
NHNdema Abu Habib
Ndema Abu Habib
JSJoão Paulo Souza
João Paulo Souza
AGA Metin Gülmezoglu
A Metin Gülmezoglu
TDTherese Dowswell
Therese Dowswell
OOOlufemi T Oladapo
Olufemi T Oladapo
In 2001, the WHO Antenatal Care Trial (WHOACT) concluded that an antenatal care package of evidence-based screening, therapeutic interventions and education across four antenatal visits for low-risk women was not inferior to standard antenatal care and may reduce cost. However, an updated Cochrane review in 2010 identified an increased risk of perinatal mortality of borderline statistical significance in three cluster-randomized trials (including the WHOACT) in developing countries. We conducted a secondary analysis of the WHOACT data to determine the relationship between the reduced visits, goal-oriented antenatal care package and perinatal mortality. Exploratory analyses were conducted to assess the effect of baseline risk and timing of perinatal death. Women were stratified by baseline risk to assess differences between intervention and control groups. We used linear modeling and Poisson regression to determine the relative risk of fetal death, neonatal death and perinatal mortality by gestational age. 12,568 women attended the 27 intervention clinics and 11,958 women attended the 26 control clinics. 6,160 women were high risk and 18,365 women were low risk. There were 161 fetal deaths (1.4%) in the intervention group compared to 119 fetal deaths in the control group (1.1%) with an increased overall adjusted relative risk of fetal death (Adjusted RR 1.27; 95% CI 1.03, 1.58). This was attributable to an increased relative risk of fetal death between 32 and 36 weeks of gestation (Adjusted RR 2.24; 95% CI 1.42, 3.53) which was statistically significant for high and low risk groups. It is plausible the increased risk of fetal death between 32 and 36 weeks gestation could be due to reduced number of visits, however heterogeneity in study populations or differences in quality of care and timing of visits could also be playing a role. Monitoring maternal, fetal and neonatal outcomes when implementing antenatal care protocols is essential. Implementing reduced visit antenatal care packages demands careful monitoring of maternal and perinatal outcomes, especially fetal death.

22 November 2013 in BMC Emergency Medicine
Verified
Journal Article
Open access
PDF file
SYSurakrant Yutthakasemsunt
Surakrant Yutthakasemsunt
WKWarawut Kittiwatanagul
Warawut Kittiwatanagul
PPParnumas Piyavechvirat
Parnumas Piyavechvirat
BTBandit Thinkhamrop
Bandit Thinkhamrop
NPNakornchai Phuenpathom
Nakornchai Phuenpathom
PLPisake Lumbiganon
Pisake Lumbiganon
Traumatic brain injury (TBI) is commonly accompanied by intracranial bleeding which can worsen after hospital admission. Tranexamic acid (TXA) has been shown to reduce bleeding in elective surgery and there is evidence that short courses of TXA can reduce rebleeding in spontaneous intracranial haemorrhage. We aimed to determine the effectiveness and safety of TXA in preventing progressive intracranial haemorrhage in TBI. This is a double blinded, placebo controlled randomized trial. We enrolled 238 patients older than 16 years with moderate to severe TBI (post-resuscitation Glasgow Coma Scale (GCS) 4 to 12) who had a computerized tomography (CT) brain scan within eight hours of injury and in whom there was no immediate indication for surgery. We excluded patients if they had a coagulopathy or a serum creatinine over than 2.0 milligrams%. The treatment was a single dose of 2 grams of TXA in addition to other standard treatments. The primary outcome was progressive intracranial haemorrhage (PIH) which was defined as an intracranial haemorrhage seen on the second CT scan that was not seen on the first CT scan, or an intracranial haemorrhage seen on the first scan that had expanded by 25% or more on any dimension (height, length, or width) on the second scan. Progressive intracranial haemorrhage was present in 21 (18%) of 120 patients allocated to TXA and in 32 (27%) of 118 patients allocated to placebo. The difference was not statistically significant [RR = 0.65 (95% CI 0.40 to 1.05)]. There were no significant difference in the risk of death from all causes in patients allocated to TXA compared with placebo [RR = 0.69 (95% CI 0.35 to 1.39)] and the risk of unfavourable outcome on the Glasgow Outcome Scale [RR = 0.76 (95% CI 0.46 to 1.27)]. There was no evidence of increased risk of thromboembolic events in those patients allocated to TXA. TXA may reduce PIH in patients with TBI; however, the difference was not statistically significant in this trial. Large clinical trials are needed to confirm and to assess the effect of TXA on death or disability after TBI.

6 December 2016 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
PLPisake Lumbiganon
Pisake Lumbiganon
RMRuth Martis
Ruth Martis
MLMalinee Laopaiboon
Malinee Laopaiboon
MFMario R Festin
Mario R Festin
JHJacqueline J Ho
Jacqueline J Ho
MHMohammad Hakimi
Mohammad Hakimi

17 December 2009 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
JFJ Frederik Frøen
J Frederik Frøen
SGSanne J Gordijn
Sanne J Gordijn
HAHany Abdel-Aleem
Hany Abdel-Aleem
PBPer Bergsjø
Per Bergsjø
ABAna Pilar Betrán
Ana Pilar Betrán
ASAnuraj Shankar
Anuraj Shankar
Stillbirths need to count. They constitute the majority of the world's perinatal deaths and yet, they are largely invisible. Simply counting stillbirths is only the first step in analysis and prevention. From a public health perspective, there is a need for information on timing and circumstances of death, associated conditions and underlying causes, and availability and quality of care. This information will guide efforts to prevent stillbirths and improve quality of care.